Methylene Blue and G6PD Deficiency: An Absolute Contraindication You Must Screen For
G6PD deficiency turns methylene blue from a treatment into a hemolysis trigger. Learn the mechanism, who is at risk, and why screening is non-negotiable.
G6PD deficiency turns methylene blue from a treatment into a hemolysis trigger. Learn the mechanism, who is at risk, and why screening is non-negotiable.
An honest look at methylene blue’s proposed mitochondrial and MAO-inhibiting mechanisms for brain fog and fatigue, with critical safety warnings for human use.
Methylene blue dosage depends on the goal: learn the low-dose nootropic range, FDA-approved clinical dosing, and the critical safety limits you must not cross.
Compare methylene blue liquid drops, capsules, and sublingual troches — absorption, dosing, purity requirements, and safety considerations explained.